Refractory autoimmune thrombocytopenic purpura treatment with Rituximab [4]

American Journal of Hematology

Volumn 67, Issue 1, 2001, Pages 59-60

  Patel, Kashyap ^a   Berman, Jessica ^a   Ferber, Andres ^a   Caro, Jaime ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB; STEROID;

ADULT; AUTOIMMUNE DISEASE; CASE REPORT; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA;

EID: 0035059346     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.1081     Document Type: Letter

References (5)

1. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of the patients responded to a four-dose treatment program
3. Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP)
4. Rituximab for the treatment of refractory immune thromhocytopenic purpura - Case report
5. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune mediated thrombocytopenia in a patient with chronic graft-versus-host disease